IONS - IONIS PHARMACEUTICALS INC

74.78
-0.090   -0.120%

Share volume: 1,818,784
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$74.87
-0.09
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
38%
Profitability 16%
Dept financing 47%
Liquidity 75%
Performance 48%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.23%
1 Month
5.64%
3 Months
-8.57%
6 Months
4.59%
1 Year
157.60%
2 Year
82.08%
Key data
Stock price
$74.78
P/E Ratio 
0.00
DAY RANGE
$73.80 - $75.96
EPS 
-$2.38
52 WEEK RANGE
$28.79 - $86.74
52 WEEK CHANGE
$156.98
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-31-2025
BETA 
0.45
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,579,068
AVERAGE 30 VOLUME 
$1,804,084
Company detail
CEO: Brett P. Monia
Region: US
Website: ionispharma.com
Employees: 800
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.

Recent news